Results 21 to 30 of about 901 (171)

A rare complication of coronary vasospasm associated with concomitant use of ergotamine, cobicistat, and darunavir

Antiviral Therapy, 2022
Ergotism is a rare cause of peripheral vasoconstriction with varying presentation depending on the affected vessels. Coronary vasospasm is a rare, potentially fatal manifestation of ergotism.
Cheng-En Wu, Chun-Hsien Wu, Shih-Hung Tsai, Wen-I Liao   +3 more
doaj   +1 more source

Pharmacological aspects of darunavir/cobicistat [PDF]

, 2016
Rezolsta® (darunavir/cobicistat) es el primer inhibidor de la proteasa potenciado en combinación fija con un nuevo potenciador farmacológico. Darunavir es actualmente el inhibidor de la proteasa de uso preferente con un perfil de eficacia y seguridad ...
Santos-González, Jesús Leandro, González-Doménech, Carmen María, Palacios-Muñoz, María Rosario   +2 more
core   +1 more source

Treatment-related early discontinuations and adverse events among newly diagnosed people living with HIV initiating integrase inhibitors in a real-world setting

Antiviral Therapy, 2023
Background Cohort studies suggest higher discontinuation rates with integrase strand transfer inhibitors (INSTIs) than are seen in clinical trials. We assessed discontinuations and adverse events (AEs) that were considered related to the initial INSTI in
Charlotte-Paige Rolle MD, MPH, Jamie Castano, Vu Nguyen MS, Kiran Patel, Federico Hinestrosa MD, Edwin DeJesus MD   +5 more
doaj   +1 more source

Biotransformation of Cobicistat: Metabolic Pathways and Enzymes [PDF]

Drug Metabolism Letters, 2016
Cobicistat (COBI) is a pharmacoenhancer for antiretroviral therapy.The current study was designed to profile the metabolic pathways of COBI and to determine the enzymes that contribute to COBI metabolism.We screened COBI metabolites in mice and human liver microsomes. We also used cDNAexpressed human cytochromes P450 (CYPs) to explore the role of human
Pengcheng, Wang, Amina I, Shehu, Ke, Liu, Jie, Lu, Xiaochao, Ma   +4 more
openaire   +2 more sources

Cobicistat as a Potential Booster of Ponatinib and Dasatinib Exposure in a CML Patient: A Case Study [PDF]

, 2023
The authors present a case of a 57-year-old patient with chronic myeloid leukemia who was treated with ponatinib and subsequently treated with dasatinib.
Oude Munnink, Thijs H, Susan Hofman, Bart F. R. Span, Hofman, Susan, Span, Bart F R, Thijs H. Oude Munnink, Oude Munnink, Thijs H; id_orcid, Touw, Daan J, Touw, Daan J; id_orcid, Daan J. Touw   +9 more
core   +1 more source

Cobicistat Versus Ritonavir: Similar Pharmacokinetic Enhancers But Some Important Differences

, 2017
Objective: To describe properties of cobicistat and ritonavir; compare boosting data with atazanavir, darunavir, and elvitegravir; and summarize antiretroviral and comedication interaction studies, with a focus on similarities and differences between ...
Jason Seet, Janet Wu, Alice Tseng, Elizabeth J. Phillips, Christine A. Hughes   +4 more
core   +2 more sources

Rifabutin-Cobicistat Drug Interaction Resulting in Severe Bilateral Panuveitis

Case Reports in Ophthalmology, 2020
We report a novel case of severe bilateral panuveitis with hypopyon secondary to rifabutin and cobicistat drug interaction in the setting of human immunodeficiency virus (HIV) infection and latent tuberculosis (TB).
Christopher B. Toomey, Jeffrey Lee, Doran B. Spencer   +2 more
doaj   +1 more source

Elvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIV [PDF]

, 2018
OBJECTIVE: To evaluate elvitegravir and cobicistat pharmacokinetics during pregnancy compared with postpartum and in infant washout samples after delivery.
Smith, Elizabeth, Burchett, Sandra, Wang, Jiajia, Badell, Martina L, Acosta, Edward P, Best, Brookie M, Barr, Emily, Purswani, Murli, Capparelli, Edmund V, Chakhtoura, Nahida, Stek, Alice, Mirochnick, Mark, Park, Kyunghun, Momper, Jeremiah D, Shapiro, David E   +14 more
core   +1 more source

Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?

Journal of Virus Eradication, 2018
Background: Higher plasma tenofovir concentrations are associated with higher risks of renal and bone adverse events. The pharmacokinetic boosters ritonavir (RTV) and cobicistat (COBI) significantly increase plasma area under the curve (AUC ...
Andrew Hill, Sophie L. Hughes, Dzintars Gotham, Anton L. Pozniak   +3 more
doaj   +1 more source

Population Pharmacokinetics of Cobicistat and its Effect on the Pharmacokinetics of the Anticancer Drug Olaparib [PDF]

Objectives: Pharmacokinetic (PK) boosting is the intentional use of strong inhibitors of metabolic enzymes or transporters to boost the systemic exposure of a therapeutic drug.
Burger, David M., ter Heine, Rob, Overbeek, Joanneke K., Koolen, Stijn L.W., den Broeder, Alfons A., Huitema, Alwin D.R., van Erp, Nielka P.   +6 more
core   +3 more sources